Catecholamines 101.
This review of clinical catecholamine neurochemistry is based on the Streeten Memorial Lecture at the 19th annual meeting of the American Autonomic Society and lectures at a satellite of the 6th Congress of the International Society of Autonomic Neuroscience. Here I provide historical perspective, describe sources and meanings of plasma levels of catecholamines and their metabolites, present a model of a sympathetic noradrenergic neuron that conveys how particular aspects of sympathetic nervous function affect plasma levels of catecholamines and their metabolites, and apply the model to understand plasma neurochemical patterns associated with some drugs and disease states.
Goldstein
David S
DS
Clinical Neurocardiology Section, Clinical Neurosciences Program, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive MSC-1620, 9000 Rockville Pike, Bldg. 10 Rm. 5N220, Bethesda, MD 20892, USA. goldsteind@ninds.nih.gov
D000818:Animals; D001341:Autonomic Nervous System / Q000378:metabolism; D001342:Autonomic Nervous System Diseases / Q000378:metabolism; D002395:Catecholamines / Q000096:biosynthesis / Q000097:blood / Q000266:history / Q000502:physiology*; D018678:Cholinergic Agents / Q000494:pharmacology; D049673:History, 20th Century; D006801:Humans; D008959:Models, Neurological; D009613:Nobel Prize; D010275:Parasympathetic Nervous System / Q000187:drug effects / Q000378:metabolism / Q000502:physiology
D002395:Catecholamines; D018678:Cholinergic Agents